Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 10/20 | 0.68 |
| ▸ | SLC1A2 | P43004 | 9/20 | 0.68 |
| ▸ | SLC1A3 | P43003 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288385 | 1.00 | SLC1A1 (0.68) | SLC1A1SLC1A2SLC1A3MEN1CYP1A2 | |
| SCHEMBL31606672 | 1.00 | SLC1A1 (0.68) | SLC1A1SLC1A2SLC1A3MEN1CYP1A2 | |
| SCHEMBL18325959 | 1.00 | SLC1A1 (0.68) | SLC1A1SLC1A2SLC1A3MEN1CYP1A2 | |
| SCHEMBL14037383 | 1.00 | SLC1A1 (0.68) | SLC1A1SLC1A2SLC1A3MEN1CYP1A2 | |
| SCHEMBL289127 | 1.00 | SLC1A1 (0.68) | SLC1A1SLC1A2SLC1A3MEN1CYP1A2 | |
| SCHEMBL8464720 | 1.00 | SLC1A1 (0.68) | SLC1A1SLC1A2SLC1A3MEN1CYP1A2 | |
| SCHEMBL562232 | 1.00 | SLC1A1 (0.68) | SLC1A1SLC1A2SLC1A3MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL20820005 | 0.98 | SLC1A1 (0.66) | SLC1A1SLC1A2SLC1A3MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL15670199 | 0.98 | SLC1A1 (0.66) | SLC1A1SLC1A2SLC1A3MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL3334189 | 0.98 | SLC1A1 (0.66) | SLC1A1SLC1A2SLC1A3MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 531 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | KINTSUGI THERAPEUTICS S L (ES) | 2025-08-28 | — | — | US | claimed |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | WASHINGTON UNIVERSITY | 2025-05-29 | — | — | US | claimed |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | claimed |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | claimed |
| EP-4363436-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2024-05-08 | — | — | EP | claimed |
| CN-117940444-A | Caspase-2 inhibitor compounds | 金特速吉医疗有限责任公司 | 2024-04-26 | — | — | CN | claimed |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | claimed |
| CN-116731101-A | Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases | 雅斯娜 | 2023-09-12 | — | — | CN | claimed |
| CN-116655730-A | Derivatives of N-caproic acid-L-tyrosine-L-isoleucine- (6) -aminocaproamide for the treatment of various diseases | 雅斯娜 | 2023-08-29 | — | — | CN | claimed |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ZEALAND PHARMA A/S (DK) | 2023-08-01 | — | — | US | claimed |
| EP-0709373-B1 | PYRROLIDINE DERIVATIVE | ZAIDAN HOJIN BISEIBUTSU (JP) | 2001-10-17 | — | — | EP | claimed |
| US-5753619-A | CYCLIC HEPTAPEPTIDES FOR CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INSUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | claimed |
| EP-0714909-A1 | Composition for prophylaxis or treatment of pulmonary circulatory diseases | Takeda Chemical Industries, Ltd. (JP) | 1996-06-05 | — | — | EP | claimed |
| EP-0272671-B1 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD (CH) | 1994-03-16 | — | — | EP | claimed |
| US-5055451-A | Prevent tissue damage | SYNTEX INC. (US) | 1991-10-08 | — | — | US | claimed |
| EP-0272671-A2 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD. (CH) | 1988-06-29 | — | — | EP | claimed |
| EP-0154581-B1 | ALPHA-CHLORINATED CARBONATES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION TO THE PROTECTION OF AMINIC FUNCTIONS IN AMINO ACIDS | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1988-06-08 | — | — | EP | claimed |
| US-4483807-A | Process for producing a slow release composite | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1984-11-20 | — | — | US | claimed |
| EP-0036713-B1 | ANGIOTENSIN CONVERTING ENZYME INHIBITORS | UNIVERSITY OF MIAMI (US) | 1984-01-18 | — | — | EP | claimed |
| US-3936469-A | Process for preparing N-carboxylic anhydrides of amino acids | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JA) | 1976-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | SLC1A1 2206/4885SLC1A2 2364/4885SLC1A3 2200/4885 |
| US-20250270255-A1 | CASPASE-2 INHIBITOR COMPOUNDS | CASP2, CASP1, CASP3 | SLC1A1 4633/4885SLC1A2 3886/4885SLC1A3 4619/4885 |
| US-20250171495-A1 | MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION | TMPRSS2, PRSS1, PRSS2 | SLC1A1 3965/4885SLC1A2 4203/4885SLC1A3 4284/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | SLC1A1 2900/4885SLC1A2 4069/4885SLC1A3 3008/4885 |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | SLC1A1 3228/4885SLC1A2 4250/4885SLC1A3 3302/4885 |
| US-11713338-B2 | Cyclic peptides multimers targeting α-4-β-7 integrin | ITGB7, ITGB4, ITGA4 | SLC1A1 3416/4885SLC1A2 4384/4885SLC1A3 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.